According to the Zhitong Finance App, Xintiandi (301277.SZ) issued an announcement. On July 21, 2026, the company received the “Notice of Approval of the Marketing Application for Chemical Ingredients” for the active ingredient amlodipine benzenesulfonate approved and issued by the State Drug Administration. This drug is a long-acting calcium channel blocker and has the effect of relaxing blood vessels and improving blood circulation. It is indicated for high blood pressure, coronary heart disease, and can also be used for chronic angina pectoris and vasospastic angina pectoris, and can be treated alone or in combination with other drugs.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.